These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 25965416)

  • 1. Use of Fixed Dose Combination (FDC) Drugs in India: Central Regulatory Approval and Sales of FDCs Containing Non-Steroidal Anti-Inflammatory Drugs (NSAIDs), Metformin, or Psychotropic Drugs.
    McGettigan P; Roderick P; Mahajan R; Kadam A; Pollock AM
    PLoS Med; 2015 May; 12(5):e1001826; discussion e1001826. PubMed ID: 25965416
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fixed dose combinations of anti-tubercular, antimalarial and antiretroviral medicines on the Indian market: critical analysis of ubiquity, sales and regulatory status.
    Ligade VS; Thakar TM; Dengale SJ
    Trop Med Int Health; 2019 Feb; 24(2):238-246. PubMed ID: 30422371
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Threats to global antimicrobial resistance control: Centrally approved and unapproved antibiotic formulations sold in India.
    McGettigan P; Roderick P; Kadam A; Pollock A
    Br J Clin Pharmacol; 2019 Jan; 85(1):59-70. PubMed ID: 29397576
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory enforcement of the marketing of fixed-dose combinations in India: a case study of systemic antibiotics.
    Brhlikova P; Mehta A; McGettigan P; Pollock AM; Roderick P; Farooqui HH
    J Pharm Policy Pract; 2023 Nov; 16(1):139. PubMed ID: 37950272
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Adequacy of clinical trial evidence of metformin fixed-dose combinations for the treatment of type 2 diabetes mellitus in India.
    Evans V; Roderick P; Pollock AM
    BMJ Glob Health; 2018; 3(2):e000263. PubMed ID: 29527355
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consumption of systemic antibiotics in India in 2019.
    Koya SF; Ganesh S; Selvaraj S; Wirtz VJ; Galea S; Rockers PC
    Lancet Reg Health Southeast Asia; 2022 Sep; 4():100025. PubMed ID: 37383993
    [TBL] [Abstract][Full Text] [Related]  

  • 7. India's ban on antimicrobial fixed-dose combinations: winning the battle, losing the war?
    Sulis G; Pradhan R; Kotwani A; Gandra S
    J Pharm Policy Pract; 2022 Apr; 15(1):33. PubMed ID: 35484606
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Fixed-dose combinations banned in India: is it the right decision? An eye-opening review.
    Miranda MRH; Dubey A; G S R; Charyulu RN
    Expert Opin Drug Saf; 2019 Oct; 18(10):977-985. PubMed ID: 31374180
    [No Abstract]   [Full Text] [Related]  

  • 9. Assessment of rationality of available fixed dose combinations of antibiotics in India.
    Anand P; Kaur N; Verma V; Shafiq N; Malhotra S
    Expert Rev Anti Infect Ther; 2022 May; 20(5):797-808. PubMed ID: 34865581
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Systemic antibiotic sales and WHO recommendations, India.
    Mehta A; Brhlikova P; McGettigan P; Pollock AM; Roderick P; Farooqui HH
    Bull World Health Organ; 2022 Oct; 100(10):610-619. PubMed ID: 36188020
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High global consumption of potentially inappropriate fixed dose combination antibiotics: Analysis of data from 75 countries.
    Bortone B; Jackson C; Hsia Y; Bielicki J; Magrini N; Sharland M
    PLoS One; 2021; 16(1):e0241899. PubMed ID: 33471786
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Assessment of Rationality of Fixed Dose Combinations Approved in CDSCO List.
    Dalal K; Ganguly B; Gor A
    J Clin Diagn Res; 2016 Apr; 10(4):FC05-8. PubMed ID: 27190825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Fixed drug combinations for the acute treatment of migraine : place in therapy.
    Loder E
    CNS Drugs; 2005; 19(9):769-84. PubMed ID: 16142992
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical Analysis of Cardiovascular and Central Nervous System Fixed Dose Combinations Available in Indian Market.
    Prajapati K; Shah S; Desai M
    J Clin Diagn Res; 2016 Dec; 10(12):FC36-FC39. PubMed ID: 28149832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical Benefits of Fixed Dose Combinations Translated to Improved Patient Compliance.
    Arya DS; Chowdhury S; Chawla R; Das AK; Ganie MA; Kumar KMP; Nadkar MY; Rajput R
    J Assoc Physicians India; 2019 Dec; 67(12):58-64. PubMed ID: 31801333
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A study of use of fixed dose combinations in Ahmedabad, India.
    Balat JD; Gandhi AM; Patel PP; Dikshit RK
    Indian J Pharmacol; 2014; 46(5):503-9. PubMed ID: 25298579
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Investigation of bioequivalence of a new fixed-dose combination of acarbose and metformin with the corresponding loose combination as well as the drug-drug interaction potential between both drugs in healthy adult male subjects.
    Kim S; Jang IJ; Shin D; Shin DS; Yoon S; Lim KS; Yu KS; Li J; Zhang H; Liu Y; Brendel E; Blode H; Wang Y
    J Clin Pharm Ther; 2014 Aug; 39(4):424-31. PubMed ID: 24806030
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evergreened drugs or evergreened profits?
    Siddalingaiah S; Fugh-Berman A
    J Eval Clin Pract; 2022 Dec; 28(6):1119-1126. PubMed ID: 35543377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bioequivalence of saxagliptin/metformin extended-release (XR) fixed-dose combination tablets and single-component saxagliptin and metformin XR tablets in healthy adult subjects.
    Boulton DW; Smith CH; Li L; Huang J; Tang A; LaCreta FP
    Clin Drug Investig; 2011; 31(9):619-30. PubMed ID: 21819160
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.